Open Orphan (ORPH), a specialist contract research organisation, said it is developing the world’s first Omicron human challenge model.
hVIVO to develop the world’s first Omicron human challenge model
OneThree Biotech completes build and optimisation of AI model for RSV data – results to come in H2
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Bitcoin, Avacta, Arrow, Audioboom,
Open Orphan (ORPH), a specialist contract research organisation, announced that hVIVO, a subsidiary of Open Orphan, has signed a £7.2m contract with an existing top 5 global pharmaceutical company to
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces thathVIVO,
Arrow Exploration (AXL) announced a further update on the Rio Cravo Sur-1 well located on the Tapir Block in the Llanos Basin of Colombia. Spud on May 23, 2022, the
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the
Open Orphan (ORPH), the specialist contract research organisation with a recent stunning run of contract wins, announced its audited final results for the 12 months ended 31 December 2021.
Record revenues and EBITDA-profitability accompanied by significant operational progress
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Alien, Carclo, Esken, IG, Omega, Open
